Why Two Exchange-Traded Funds Beat Direct Artificial Intelligence Stock Purchases
Two AI ETFs returned 119% and 42% in 2026, outpacing individual stock picks through diversification and reduced research burden.
Jonathan Retskoff
Top Oil Stock Investment Amid Crude Price Crash Recovery
Oil prices have crashed 49% from February peaks, creating entry opportunities for disciplined investors in oilfield services stocks that benefit from eventual recovery.
SpaceX Shares Following Recent Decline: Assessing Investment Value Now
SpaceX fell 22% from its June peak, but valuation analysis suggests the stock may still be overpriced despite the recent decline.
American Express Stock: Premium Valuation Supported By Growth Fundamentals 2026
American Express trades at a premium backed by growth guidance and stable credit, but the margin for disappointment is shrinking as analyst targets approach current prices.
Argan Stock Gains Index Inclusion Milestone – What Small Cap Investors Should Know
Argan's S&P SmallCap 600 inclusion triggered mechanical buying and 12.6% gains, but the real story is whether a $2.9 billion backlog justifies current valuations.
High Yield Stocks Worth Buying – Two Strong Picks and One Underperformer
Two dividend aristocrats and one struggling Dividend King offer contrasting lessons about yields and total returns in 2026's market.
Vanguard ETF Forecast to Outperform S&P 500 During 2026 Second Half
Vanguard's growth-focused S&P 500 ETF may outpace the broader index in 2026's second half if mega-cap tech recovers.
Jio 2026 IPO Expected to Break Records as Largest Indian Market Debut
Jio's $3.8 billion IPO would crown India's largest market debut ever, with August-October 2026 listing likely.
Sumitomo Metal Mining Stock Surge: Key Reasons Behind Today’s Rally
Sumitomo Metal Mining's July 3 stock surge reflects gold's rebound and a near-doubling of profit guidance on elevated metal prices.
AlzeCure Pharma Stock Rallies – Key Reasons Behind the Daily Gains
AlzeCure Pharma stock surged 365% in mid-2026 following two major pharmaceutical partnerships worth over $3 billion.